We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Gets Positive CHMP Opinion for Arthritis Drug
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the company’s marketing authorisation application (MAA) for its rheumatoid arthritis (RA) drug, Xeljanz (tofacitinib citrate; 5 mg twice daily).
Pfizer is looking to get Xeljanz, in combination with methotrexate (MTX), approved in the EU for the treatment of moderate-to-severely active RA in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).
Xeljanz is already approved as a second-line treatment for this indication. The drug may also be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. A once-daily formulation of Xeljanz was approved by the FDA in Feb 2016.
Shares of Pfizer have outperformed the Zacks classified Large Cap Pharma industry in the last one year. The stock gained 4.1% during the period, while the industry registered a decline of 2.4%.
The MAA was supported by data from the Oral Rheumatoid Arthritis phase III Trials (ORAL) global development program. The program consisted of six clinical trials and two open-label long-term extension (LTE) studies. The ORAL development program had collected more than 19,000 patient-years of drug exposure in over 6,100 patients with follow-up observations of up to eight years in one of the LTE studies.
Presently, Xeljanz is being evaluated in phase III studies for the treatment of ulcerative colitis.
We remind investors that in Jul 2013, the CHMP had recommended against the approval of Xeljanz for the treatment of adults with moderate-to-severely active RA. The committee was of the opinion that the drug had failed to demonstrate a favorable benefit-risk profile. It had also revealed underlying concerns related to safety as well as serious infections.
Xeljanz has been generating strong sales in the U.S. In the first nine months of 2016, it garnered revenues of $649 million, up an impressive 85% year over year.
According to information provided by the company, approximately 17.6 million individuals in the world and 2.9 million individuals in Europe are affected by RA. Hence, approval of the drug will provide the company access to a huge patient population affected by the disease.
Note that on the same day, the CHMP granted a positive opinion to Amgen, Inc.’s (AMGN - Free Report) biosimilar version of AbbVie, Inc. (ABBV - Free Report) Humira for the treatment of RA. Other drugs approved for this indication include Roche Holding AG’s (RHHBY - Free Report) Actemra and Bristol-Myers Squibb’s Orencia.
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Pfizer (PFE) Gets Positive CHMP Opinion for Arthritis Drug
Pfizer Inc. (PFE - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the company’s marketing authorisation application (MAA) for its rheumatoid arthritis (RA) drug, Xeljanz (tofacitinib citrate; 5 mg twice daily).
Pfizer is looking to get Xeljanz, in combination with methotrexate (MTX), approved in the EU for the treatment of moderate-to-severely active RA in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).
Xeljanz is already approved as a second-line treatment for this indication. The drug may also be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. A once-daily formulation of Xeljanz was approved by the FDA in Feb 2016.
Shares of Pfizer have outperformed the Zacks classified Large Cap Pharma industry in the last one year. The stock gained 4.1% during the period, while the industry registered a decline of 2.4%.
The MAA was supported by data from the Oral Rheumatoid Arthritis phase III Trials (ORAL) global development program. The program consisted of six clinical trials and two open-label long-term extension (LTE) studies. The ORAL development program had collected more than 19,000 patient-years of drug exposure in over 6,100 patients with follow-up observations of up to eight years in one of the LTE studies.
Presently, Xeljanz is being evaluated in phase III studies for the treatment of ulcerative colitis.
We remind investors that in Jul 2013, the CHMP had recommended against the approval of Xeljanz for the treatment of adults with moderate-to-severely active RA. The committee was of the opinion that the drug had failed to demonstrate a favorable benefit-risk profile. It had also revealed underlying concerns related to safety as well as serious infections.
Xeljanz has been generating strong sales in the U.S. In the first nine months of 2016, it garnered revenues of $649 million, up an impressive 85% year over year.
According to information provided by the company, approximately 17.6 million individuals in the world and 2.9 million individuals in Europe are affected by RA. Hence, approval of the drug will provide the company access to a huge patient population affected by the disease.
Note that on the same day, the CHMP granted a positive opinion to Amgen, Inc.’s (AMGN - Free Report) biosimilar version of AbbVie, Inc. (ABBV - Free Report) Humira for the treatment of RA. Other drugs approved for this indication include Roche Holding AG’s (RHHBY - Free Report) Actemra and Bristol-Myers Squibb’s Orencia.
Pfizer, Inc. Price
Pfizer, Inc. Price | Pfizer, Inc. Quote
Zacks Rank
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>